Program
zenagamtide
Also written as “NNC0487-0111”, “Zenagamtide” and “NNC0487-0111 A”.
In Novo Nordisk's own words, Zenagamtide is the first of its class, being a unimolecular peptide agonist of GLP-1 and amylin receptors.
. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by Novo Nordisk.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 3526 open or running | phase 3since Jan 13, 2026 | May 4, 2022 | Nov 11, 2027phase 1 · NCT07535307 |
- Named in Novo Nordisk’s own pipeline as
Zenagamtide (sc and oral)
, phase 3, as of Nov 5, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since May 4, 2022.
- Feb 3, 2026Phase 3 study in ObesityNCT07400107 · 985 enrolled · United States, Argentina, Brazil and more
- Mar 13, 20263 phase 3 studies in ObesityNCT07481630, NCT07503210, NCT07509307
- Mar 27, 2026Phase 1 study in ObesityNCT07508020 · 120 planned · Germany
- Apr 9, 2026Phase 1 study in Diabetes MellitusNCT07535307 · 80 planned · Germany
- Apr 9, 20264 phase 3 studiesNCT07533175, NCT07567001, NCT07571109 and 1 more
- May 8, 2026Phase 1 study in OverweightNCT07587710 · 35 planned · Slovakia
- Jun 18, 20262 phase 3 studiesNCT07668401, NCT07668414
- Jul 17, 2026Phase 3 study in OverweightNCT07720271 · 950 planned · United States
- Jul 30, 2026Phase 1 study in OverweightNCT07757087 · 120 planned · Denmark, Netherlands
- Aug 26, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07797335 · 1,778 planned · United States, Argentina, Brazil and more
- Sep 6, 20262 phase 1 studies in OverweightNCT07815067, NCT07855133
- Sep 10, 20262 phase 3 studiesNCT07822061, NCT07861100
- Oct 5, 2026Phase 1 study in OverweightNCT07868354 · 60 planned · United States
- Nov 6, 20264 phase 3 studies in Diabetes Mellitus, Type 2NCT07931599, NCT07931573, NCT07931547 and 1 more
Ahead
- Nov 11, 2027Primary completion: phase 1 study in Diabetes MellitusNCT07535307
- Dec 1, 2027Primary completion: phase 1 study in OverweightNCT07587710
- Jan 19, 2028Primary completion: phase 1 study in ObesityNCT07508020
- Jun 5, 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07931495
TargetBeta
“Zenagamtide is the first of its class, being a unimolecular peptide agonist of GLP-1 and amylin receptors.”company, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| CagriSema A | Novo Nordisk | phase 1 | 1 |
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07931599Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Not yet recruiting | Jul 24, 2028 | 1,060 |
| NCT07931573Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Not yet recruiting | Jul 4, 2028 | 1,200 |
| NCT07931547Diabetes Mellitus, Type 2 · United States, Brazil, China and more | 3 | Not yet recruiting | Jul 31, 2028 | 450 |
| NCT07931495Diabetes Mellitus, Type 2 · United States, China, Japan and more | 3 | Not yet recruiting | Jun 5, 2028 | 200 |
| NCT07868354Overweight · United States | 1 | Recruiting | Sep 7, 2028 | 60 |
| NCT07861100Obesity · United States, Argentina, Australia and more | 3 | Not yet recruiting | Sep 16, 2030 | 8,500 |
| NCT07855133Overweight · United States | 1 | Recruiting | Sep 6, 2028 | 60 |
| NCT07822061Overweight · Japan | 3 | Recruiting | Feb 5, 2029 | 400 |
| NCT07815067Overweight · Germany | 1 | Recruiting | Jun 12, 2028 | 320 |
| NCT07797335Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Recruiting | Jul 31, 2028 | 1,778 |
| NCT07757087Overweight · Denmark, Netherlands | 1 | Recruiting | Sep 18, 2028 | 120 |
| NCT07720271Overweight · United States | 3 | Recruiting | Jun 27, 2028 | 950 |
| NCT07668414Overweight · United States | 3 | Recruiting | Oct 10, 2028 | 650 |
| NCT07668401Obesity · India, Japan, Malaysia and more | 3 | Not yet recruiting | Jan 11, 2029 | 400 |
| NCT07587710Overweight · Slovakia | 1 | Recruiting | Dec 1, 2027 | 35 |
| NCT07571109Obesity · United States, Australia, China and more | 3 | Recruiting | Jun 26, 2028 | 300 |
| NCT07571005Obesity · United States, Australia, China and more | 3 | Recruiting | Jul 12, 2028 | 300 |
| NCT07567001Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Jul 23, 2029 | 5,610 |
| NCT07535307Diabetes Mellitus · Germany | 1 | Recruiting | Nov 11, 2027 | 80 |
| NCT07533175Diabetes Mellitus · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Aug 7, 2028 | 638 |
| NCT07509307Obesity · United States, Australia, Bulgaria and more | 3 | Recruiting | Aug 14, 2028 | 400 |
| NCT07508020Obesity · Germany | 1 | Recruiting | Jan 19, 2028 | 120 |
| NCT07503210Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jun 6, 2028 | 606 |
| NCT07481630Obesity · United States, Australia, Bulgaria and more | 3 | Recruiting | Aug 14, 2028 | 400 |
| NCT07400107Obesity · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Dec 19, 2028 | 985 |
| NCT07339423Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Jun 26, 2029 | 1,150 |
| NCT07121153Overweight · China | 1 | Completed | Dec 20, 2025 | 36 |
| NCT06820476Overweight · China | 1 | Completed | May 14, 2025 | 29 |
| NCT06559527Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Feb 24, 2025 | 42 |
| NCT06542874Diabetes Mellitus, Type 2 · United States, Bulgaria, Croatia and more | 2 | Completed | Oct 1, 2025 | 448 |
| NCT06478563Obesity · United States | 1 | Completed | Jun 5, 2025 | 133 |
| NCT06461039Obesity · Canada | 1 | Completed | Mar 16, 2025 | 43 |
| NCT06064006Obesity · United States | 2 | Completed | Nov 27, 2024 | 125 |
| NCT06049329Obesity · Japan | 1 | Completed | Dec 15, 2023 | 36 |
| NCT05369390Obesity · United States | 1 | Completed | Jan 9, 2024 | 144 |
How it is read
Names in the registry
- “NNC0487-0111”, 18 entries
- “Zenagamtide”, 10 entries
- “NNC0487-0111 A”, 3 entries
- “Zenagamtide injection”, 1 entry
- “Zenagamtide tablet”, 1 entry
Codes read as this program: NNC04870111.
Conditions, from the studies’ own filings
- Obesity, 26 studies
- Diabetes Mellitus, Type 2, 7 studies
- Diabetes Mellitus, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.